Back to top

Is Molina Healthcare (MOH) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Molina Healthcare (MOH - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Molina Healthcare is one of 757 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. MOH is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for MOH's full-year earnings has moved 44.28% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Based on the most recent data, MOH has returned 80.41% so far this year. Meanwhile, the Medical sector has returned an average of 7.56% on a year-to-date basis. As we can see, Molina Healthcare is performing better than its sector in the calendar year.

Looking more specifically, MOH belongs to the Medical - HMOs industry, which includes 13 individual stocks and currently sits at #20 in the Zacks Industry Rank. Stocks in this group have gained about 22.29% so far this year, so MOH is performing better this group in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on MOH as it attempts to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Molina Healthcare, Inc (MOH) - free report >>

More from Zacks Tale of the Tape

You May Like